Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.69 |
| ▸ | TP53 | P04637 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902701 | 0.95 | MAPT (0.62) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4902463 | 0.93 | MAPT (0.66) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4899842 | 0.92 | MAPT (0.65) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4900521 | 0.91 | MAPT (0.67) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4902471 | 0.91 | MAPT (0.65) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4904133 | 0.91 | MAPT (0.69) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4902600 | 0.90 | LMNA (0.64) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4908934 | 0.90 | LMNA (0.57) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4908317 | 0.89 | MAPT (0.55) | MAPTTP53LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL4909112 | 0.89 | MAPT (0.57) | MAPTTP53LMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | MAPT 1858/4885TP53 3260/4885LMNA 317/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | MAPT 1786/4885TP53 3421/4885LMNA 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.